Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 9, Pages 4467
Publisher
MDPI AG
Online
2021-04-25
DOI
10.3390/ijms22094467
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- (2021) Stephen K. Brannan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Potential Role of Lumateperone—Something Borrowed? Something New?
- (2020) Joshua T. Kantrowitz JAMA Psychiatry
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
- (2020) Christoph U. Correll et al. JAMA Psychiatry
- Potential Roles of Redox Dysregulation in the Development of Schizophrenia
- (2020) Diana O. Perkins et al. BIOLOGICAL PSYCHIATRY
- Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
- (2020) Michelle Kokkinou et al. MOLECULAR PSYCHIATRY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
- (2020) Susan F. Sonnenschein et al. NEUROPSYCHOPHARMACOLOGY
- Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
- (2020) Susan F. Sonnenschein et al. Frontiers in Psychiatry
- Prepubertal environmental enrichment prevents dopamine dysregulation and hippocampal hyperactivity in MAM schizophrenia model rats.
- (2020) Xiyu Zhu et al. BIOLOGICAL PSYCHIATRY
- Stress impacts corticoamygdalar connectivity in an age-dependent manner
- (2020) Daniela L. Uliana et al. NEUROPSYCHOPHARMACOLOGY
- Stress during critical periods of development and risk for schizophrenia
- (2019) Felipe V. Gomes et al. SCHIZOPHRENIA RESEARCH
- T108. AUT00206, A NOVEL KV3 CHANNEL MODULATOR, REDUCES KETAMINE-INDUCED BOLD SIGNALLING IN HEALTHY MALE VOLUNTEERS: A RANDOMISED PLACEBO-CONTROLLED CROSSOVER TRIAL
- (2019) Bill Deakin et al. SCHIZOPHRENIA BULLETIN
- SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION
- (2019) Nina Dedic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner
- (2019) J. J. Donegan et al. Nature Communications
- The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability
- (2019) Felipe V. Gomes et al. MOLECULAR PSYCHIATRY
- Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies
- (2019) Stephen J. Kaar et al. JOURNAL OF NEURAL TRANSMISSION
- The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [11C]-(+)-PHNO PET study
- (2019) Tarik Dahoun et al. Translational Psychiatry
- Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate
- (2018) Stephen M. Stahl CNS SPECTRUMS
- α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia
- (2018) Gilda A Neves et al. NEUROPSYCHOPHARMACOLOGY
- The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention
- (2018) Anthony A Grace et al. SCHIZOPHRENIA BULLETIN
- State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia
- (2018) Susan F. Sonnenschein et al. NEUROPSYCHOPHARMACOLOGY
- Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
- (2018) Kimberly E. Vanover et al. NEUROPSYCHOPHARMACOLOGY
- K v 3.1/K v 3.2 channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons
- (2017) Kim Boddum et al. NEUROPHARMACOLOGY
- Kv3 Channels: Enablers of Rapid Firing, Neurotransmitter Release, and Neuronal Endurance
- (2017) Leonard K. Kaczmarek et al. PHYSIOLOGICAL REVIEWS
- N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
- (2017) Philippe Conus et al. SCHIZOPHRENIA BULLETIN
- M102. Prefrontal Cortex Dysfunction Increases Susceptibility to Schizophrenia-Like Changes Induced by Adolescent Stress Exposure
- (2017) Felipe Gomes et al. SCHIZOPHRENIA BULLETIN
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Chieh-Hsin Lin et al. BIOLOGICAL PSYCHIATRY
- Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: Pilot study
- (2017) Chrysa Retsa et al. SCHIZOPHRENIA RESEARCH
- Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam
- (2016) Yijuan Du et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Modelling the cognitive and neuropathological features of schizophrenia with phencyclidineAbdul-MonimZNeillJCReynoldsGP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol21:198–205.
- (2016) Gavin P Reynolds et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression
- (2016) Anthony A. Grace NATURE REVIEWS NEUROSCIENCE
- Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release
- (2016) Daniel J. Foster et al. NEURON
- Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration
- (2016) Yijuan Du et al. NEUROPSYCHOPHARMACOLOGY
- Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model
- (2016) Felipe V. Gomes et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
- (2016) J. Lally et al. PSYCHOLOGICAL MEDICINE
- Adversity in childhood linked to elevated striatal dopamine function in adulthood
- (2016) Alice Egerton et al. SCHIZOPHRENIA RESEARCH
- Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population
- (2016) Hannah J. Jones et al. JAMA Psychiatry
- Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia
- (2015) Bruce J. Kinon et al. BIOLOGICAL PSYCHIATRY
- Alterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia
- (2015) Guillermo Gonzalez-Burgos et al. BIOLOGICAL PSYCHIATRY
- The GABA System in Schizophrenia: Cells, Molecules and Microcircuitry
- (2015) Francine M. Benes SCHIZOPHRENIA RESEARCH
- GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
- (2015) Stephan Heckers et al. SCHIZOPHRENIA RESEARCH
- Schizophrenia
- (2015) René S. Kahn et al. Nature Reviews Disease Primers
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
- (2014) AnnCatherine M Downing et al. BMC Psychiatry
- The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia
- (2014) Kathryn Gill et al. CURRENT PHARMACEUTICAL DESIGN
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model
- (2014) Kathryn M. Gill et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
- (2014) Jan-Harry Cabungcal et al. NEURON
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Prior Antipsychotic Drug Treatment Prevents Response to Novel Antipsychotic Agent in the Methylazoxymethanol Acetate Model of Schizophrenia
- (2014) K. M. Gill et al. SCHIZOPHRENIA BULLETIN
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
- (2013) David H Adams et al. BMC Psychiatry
- Differential regulation of parvalbumin and calretinin interneurons in the prefrontal cortex during adolescence
- (2013) Adriana Caballero et al. Brain Structure & Function
- Region-specific upregulation of parvalbumin-, but not calretinin-positive cells in the ventral hippocampus during adolescence
- (2013) Adriana Caballero et al. HIPPOCAMPUS
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
- (2013) E M P Poels et al. MOLECULAR PSYCHIATRY
- NMDA receptor-dependent function and plasticity in inhibitory circuits
- (2013) Alexandre W. Moreau et al. NEUROPHARMACOLOGY
- Peripubertal Diazepam Administration Prevents the Emergence of Dopamine System Hyperresponsivity in the MAM Developmental Disruption Model of Schizophrenia
- (2013) Yijuan Du et al. NEUROPSYCHOPHARMACOLOGY
- Abnormal Stress Responsivity in a Rodent Developmental Disruption Model of Schizophrenia
- (2013) Eric C Zimmerman et al. NEUROPSYCHOPHARMACOLOGY
- Perineuronal nets protect fast-spiking interneurons against oxidative stress
- (2013) J.-H. Cabungcal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cigarette Smoking Among Persons With Schizophrenia or Bipolar Disorder in Routine Clinical Settings, 1999–2011
- (2013) Faith Dickerson et al. PSYCHIATRIC SERVICES
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Stress in Puberty Unmasks Latent Neuropathological Consequences of Prenatal Immune Activation in Mice
- (2013) S. Giovanoli et al. SCIENCE
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- Mechanisms of Gamma Oscillations
- (2012) György Buzsáki et al. Annual Review of Neuroscience
- Predicting Psychosis
- (2012) Paolo Fusar-Poli ARCHIVES OF GENERAL PSYCHIATRY
- The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment
- (2012) Oliver D. Howes et al. ARCHIVES OF GENERAL PSYCHIATRY
- Glutamatergic transmission in schizophrenia
- (2012) Joshua Kantrowitz et al. CURRENT OPINION IN PSYCHIATRY
- A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
- (2012) Mark Weiser et al. JOURNAL OF CLINICAL PSYCHIATRY
- NMDA Receptor Hypofunction, Parvalbumin-Positive Neurons, and Cortical Gamma Oscillations in Schizophrenia
- (2012) G. Gonzalez-Burgos et al. SCHIZOPHRENIA BULLETIN
- Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor
- (2011) S. Espinoza et al. MOLECULAR PHARMACOLOGY
- GABAergic interneuron origin of schizophrenia pathophysiology
- (2011) Kazu Nakazawa et al. NEUROPHARMACOLOGY
- Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
- (2011) Daniela Alberati et al. NEUROPHARMACOLOGY
- A Novel α5GABAAR-Positive Allosteric Modulator Reverses Hyperactivation of the Dopamine System in the MAM Model of Schizophrenia
- (2011) Kathryn M Gill et al. NEUROPSYCHOPHARMACOLOGY
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
- (2011) Carrie K Jones et al. NEUROPSYCHOPHARMACOLOGY
- Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
- (2011) David A. Lewis et al. TRENDS IN NEUROSCIENCES
- Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
- (2010) Richard Mailman et al. CURRENT PHARMACEUTICAL DESIGN
- Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations, and Related Behaviors
- (2010) P. Steullet et al. JOURNAL OF NEUROSCIENCE
- A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors
- (2010) J. Jeon et al. JOURNAL OF NEUROSCIENCE
- The environment and schizophrenia
- (2010) Jim van Os et al. NATURE
- Metabotropic glutamate receptors: From the workbench to the bedside
- (2010) F. Nicoletti et al. NEUROPHARMACOLOGY
- Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
- (2010) Tyler A Lesh et al. NEUROPSYCHOPHARMACOLOGY
- Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion
- (2010) Alan L. Pehrson et al. PSYCHOPHARMACOLOGY
- High dose D-serine in the treatment of schizophrenia
- (2010) Joshua T. Kantrowitz et al. SCHIZOPHRENIA RESEARCH
- Trospium Chloride Treatment of Overactive Bladder
- (2009) Kelly Biastre et al. ANNALS OF PHARMACOTHERAPY
- Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia
- (2009) Daniel J. Lodge et al. NEUROTOXICITY RESEARCH
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
- (2009) O. D. Howes et al. SCHIZOPHRENIA BULLETIN
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started